Chronic lymphocytic leukaemia with transformation into a large cell lymphoma (Richter's syndrome) is usually associated with the rapid demise of these already immunocompromised patients. There have been no previously recorded cases involving the nose. We report such a case and describe a successful treatment approach combining monoclonal antibody therapy with ao mini-allogeneic bone marrow transplant. CASE REPORT A 54-year-old man presented to the otolaryngology department with a swelling on the dorsum of the nose, which had been rapidly enlarging for one month. Two years prior to this he was diagnosed with chronic lymphocytic leukaemia (CLL) and was stabilised initially with six courses of Chlorambucil. He Richter's syndrome: a novel presentation brother one year from presentation. A PCR-based assay showed that complete haemotopoietic chimaerism was achieved after the transplant, however, he also had low-grade graft versus host disease. Presently, three and half years from initial presentation, he has a normal quality of life in continuing complete remission from both the transformed disease and the CLL. Despite resolution of the nasal lesion following the CHOP regime the patient also underwent a bone marrow transplant and treatment with monoclonal antibody in order to provide him with the best chance of achieving complete remission. A high-dose conditioning regime is normally used prior to bone marrow transplantation. However, previous treatment with chemotherapy precluded mobilisation of autologous peripheral blood stem cells needed to compensate for the bone marrow suppression, which normally occurs following such a regime. He was therefore treated with a reduced dose of Fludarabine and CAMPATH-1H, a monoclonal antibody against CD52, an antigen expressed on greater than 95% of all normal human blood lymphocytes and most B and T cell lymphomas.6; 7 In the first report of the antibody, tumour regression was seen in two patients with advanced non-Hodgkin's lymphoma treated with CAMPATH-1H.8 It is currently recommended for the treatment of patients with Fludarabine refractory CLL and preliminary data suggest it is effective as a first line agent in the treatment of Bcell CLL.9; 10 By activating various immune effector functions, including antibody-dependent cellular cytotoxicity, the antibody not only targets tumour cells, it temporarily destroys the recipient's T-cells. The resultant complete donor chimaerism may reduce the risk of transplant rejection and confer a survival advantage.1" The "mini" from mini-allogeneic transplant refers to the reduced dose of chemotherapy used. To the best of our knowledge there have been no previously reported cases affecting the nose to date. A handful of cases have been described with skin involvement, however, it is rarely limited to cutaneous locations.12 It is our aim to highlight not only this novel presentation but also the encouraging result obtained from new treatment techniques with monoclonal antibody and the reduced intensity conditioning chemotherapy regime.
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